A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine

References

• Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequ Disclosure statements attached. elae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–2196.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Al Jumah M, et al. Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations. J Headache Pain. 2013;14:87.
   PubMed Web of Science ®Google Scholar
• Vos T, Barber RM, Bell B, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 Global Burden of Disease Study 2013. Lancet. 2015;386:743–800.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009;27(2):429–443.
   PubMed Web of Science ®Google Scholar
• Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007;47(3):355–363.
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644–655.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287.
   PubMed Web of Science ®Google Scholar
• Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology. 2017;89(12):1237–1243.
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby PJ, Reuter U, et al. Long-term Safety and tolerability of erenumab: three-plus year results from an ongoing open-label extension study in episodic migraine. In: 60th Annual Scientific Meeting of the American Headache Society, San Francisco, CA; 2018.
   Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Nichols R, Doty E, Sacco S, et al. Analysis of initial nonresponders to galcanezumab in patients with episodic or chronic migraine: results from the EVOLVE-1, EVOLVE-2, and REGAIN randomized, double-blind, placebo-controlled studies. Headache. 2018;59(2):192–204.
   PubMed Web of Science ®Google Scholar
• Saper J, Lipton R, Kudrow D, et al. Primary results of PROMISE-1 (prevention of migraine via intravenous eptinezumab safety and efficacy–1) trial: a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of eptinezumab for prevention of frequent episodic migraines (S20.001). Neurology. 2018;90(15 Supplement):S20.001.
   Google Scholar
• Egilius LH, Spierings TS, Cady R, et al. Repeat infusions of eptinezumab associated with greater migraine reductions and longer migraine-free intervals: results from the phase 3 PROMISE-1 trial (P4.108). Neurology. 2018;90(15 Supplement):P4.108.
   Google Scholar
• Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019;28(6):555–567.
   PubMed Web of Science ®Google Scholar
• Lambru G, Andreou AP, Guglielmetti M, et al. Emerging drugs for migraine treatment: an update. Expert Opin Emerg Drugs. 2018;23(4):301–318.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Capi M, Curto M. et al. Rimegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine. Drugs Future. 2019;44(8):635.
   Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–149.
   PubMed Web of Science ®Google Scholar
• Teva Pharmaceuticals. AJOVY [prescribing information]; 2018.
   Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–196.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183–187.
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.
   PubMed Web of Science ®Google Scholar
• Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106(3):461–470.
   PubMed Web of Science ®Google Scholar
• Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–1186.
   PubMed Web of Science ®Google Scholar
• Kruuse C, Iversen HK, Jansen-Olesen I, et al. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia. 2010;30(4):467–474.
   PubMed Web of Science ®Google Scholar
• Amrutkar DV, Ploug KB, Hay-Schmidt A, et al. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain. 2012;153(4):830–838.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Fredholm BB, Hamel E, et al. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett. 1985;58(2):213–217.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53(8):1230–1244.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. The CGRP pathway in migraine as a viable target for therapies. Headache. 2018;58(Suppl 1):33–47.
   PubMed Web of Science ®Google Scholar
• Melo-Carrillo A, Strassman AM, Nir -R-R, et al. Fremanezumab-A humanized monoclonal anti-CGRP antibody-inhibits thinly myelinated (Aδ) but not unmyelinated (C) meningeal nociceptors. J Neurosci. 2017;37(44):10587–10596.
   PubMed Web of Science ®Google Scholar
• Melo-Carrillo A, Noseda R, Nir -R-R, et al. selective inhibition of trigeminovascular neurons by fremanezumab: a humanized monoclonal anti-CGRP antibody. J Neurosci. 2017;37(30):7149–7163.
   PubMed Web of Science ®Google Scholar
• Goto T, Iwai H, Kuramoto E, et al. Neuropeptides and ATP signaling in the trigeminal ganglion. Jpn Dent Sci Rev. 2017;53(4):117–124.
   PubMed Web of Science ®Google Scholar
• Edvinsson JCA, Warfvinge K, Krause DN, et al. C-fibers may modulate adjacent Aδ-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain. 2019;20(1):105.
   PubMed Web of Science ®Google Scholar
• Cohen-Barak O, Weiss S, Rasamoelisolo M, et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia. 2018;38(13):1960–1971.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Curto M, Cisale GY, et al. Fremanezumab for the preventive treatment of migraine in adults. Expert Rev Clin Pharmacol. 2019;12(8):741–748.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999–2008.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1081–1090.
   PubMed Web of Science ®Google Scholar
• Brandes J, Yeung PP, Cohen JM, et al. Long‐Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine: Interim Results of a One‐Year Study; 2018
   Google Scholar
• VanderPluym J, Dodick DW, Lipton RB, et al. Fremanezumab for preventive treatment of migraine: functional status on headache-free days. Neurology. 2018;91(12):e1152–e65.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122.
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Sheftell FD, Tepper SJ, et al. Levetiracetam in the preventive treatmentof transformed migraine: a prospective, open-label, pilot study. Curr Ther Res Clin Exp. 2005;66(3):212–221.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Edvinsson L, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015;14(11):1091–1100.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, McAllister P, Ning X, et al. Safety and tolerability of fremanezumab for the prevention of migraine: a pooled analysis of phases 2b and 3 clinical trials. Headache. 2019;59(6):880–890.
   PubMed Web of Science ®Google Scholar
• Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain. 2017;18(1):96.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Meijer J, Villalón CM, et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37(9):779–788.
   PubMed Web of Science ®Google Scholar
• Smillie S-J, King R, Kodji X, et al. An ongoing role of α-calcitonin gene-related peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension. 2014;63(5):1056–1062.
   PubMed Web of Science ®Google Scholar
• Ohlsson L, Kronvall E, Stratton J, et al. Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries. J Headache Pain. 2018;19(1):66.
   PubMed Web of Science ®Google Scholar
• Levin M, Silberstein SD, Gilbert R, et al. Basic considerations for the use of monoclonal antibodies in migraine. Headache. 2018;58(10):1689–1696.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: effectiveness and value. Institute for Clinical and Economic Review, Boston, MA; 2018.
   Google Scholar
• Smolen L, Gandhi SK, Klein T, et al. 10-year cost-effectiveness analyses of fremanezumab as preventive treatment in chronic and episodic migraine. Value Health. 2019;22:S273.
   Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
   PubMed Web of Science ®Google Scholar
• Cowan R, Cohen JM, Rosenman E, et al. Physician and patient preferences for dosing options in migraine prevention. J Headache Pain. 2019;20(1):50.
   PubMed Web of Science ®Google Scholar